|View printer-friendly version|
|April 12, 2006 1:36 p.m.|
|Teva Announces FDA Determination that Generic Pravachol Exclusivity Has Not Been Triggered|
Jerusalem, Israel, April 12, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that further to its press release dated March 16, 2006, the U.S. Food and Drug Administration has denied Apotex's request for an agency determination that 180-day exclusivity for pravastatin 10, 20, and 40 mg has been triggered and run. Teva expects final approval with exclusivity on April 20, when the product patent expires.